May 29, 2016
Researchers at the Cleveland Clinic have been at the forefront of investigations into a promising new update to stent technology — the bioresorbable vascular scaffold.
Stephen G. Ellis, MD, director of interventional cardiology and senior academic officer for cardiology at Cleveland Clinic and co-primary investigator for the ABSORB III trial, told Cardiology Today’s Intervention. “Every year, 2% to 3% of patients have an adverse event related to the stent, and that risk seems to go on indefinitely as best we can tell. So, for the average 60-year-old — and that’s about the average age of people who receive stents — if they’re going to live another 20 years, there is a 50/50 chance they are going to have a bad outcome related to that stent over their lifetime.”
Ellis spoke with Cardiology Today’s Intervention about this ongoing risk for adverse events, the use of bioresorbable scaffolds to mitigate this risk and current research on these devices.